Kevin McCarroll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin McCarroll has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Rosaleen Lannon
Bone Health Unit, St James’s Hospital, Dublin, Ireland
9 shared publicationsDonal Fitzpatrick
Bone Health Unit, St James’s Hospital, Dublin, Ireland
8 shared publications- Eamon Laird
The Irish Longitudinal Study on Ageing, Trinity College Dublin, Dublin, Ireland
4 shared publications Finlay Brennan
Bone Health Unit, St James’s Hospital, Dublin, Ireland
4 shared publicationsAisling Carroll
Bone Health Unit, St James's Hospital, Dublin, Ireland
3 shared publications- Anne M. Molloy
School of Medicine, Trinity College, Dublin, Ireland
3 shared publications
Latest Publications
- 23 October 2026
- Published by Springer Nature in Osteoporosis International
- p. 1-3
Sustained increases in lumbar spine and hip BMD with denosumab therapy beyond 10 years
- 23 October 2026
- Published by Springer Nature in Osteoporosis International
- p. 1-3
Sustained increases in lumbar spine and hip BMD with denosumab therapy beyond 10 years
- 14 July 2026
- Published by Elsevier in Joint Bone Spine
- Vol. 93 (6) , 106103
Comment on: “Strategies for denosumab discontinuation in postmenopausal osteoporosis” by Degboé et al., Joint Bone Spine. 2026;93:105954
- 14 July 2026
- Published by Elsevier in Joint Bone Spine
- Vol. 93 (6) , 106103
Comment on: “Strategies for denosumab discontinuation in postmenopausal osteoporosis” by Degboé et al., Joint Bone Spine. 2026;93:105954
- Open Access
- 28 May 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case report
Primary hyperparathyroidism (PHPT) affects up to 1.5% of older adults, causes bone loss at cortical sites and increases fracture risk. However, atraumatic hip fractures due to PHPT are rare. We report the case of an older female diagnosed with PHPT after presenting with atraumatic bilateral neck of femur fractures. An 82-year-old white woman was referred to the emergency department with progressive left hip pain over two months and was unable to bear weight on presentation. There was no history of trauma, falls, prior fracture or diagnosis of osteoporosis. X-ray of hips showed a displaced left neck of femur fracture and a non-displaced healing right neck of femur fracture. Pelvic computed tomography (CT) confirmed X-ray findings and showed callus formation suggesting subacute fractures with no evidence of destructive lesions. Blood tests revealed hypercalcemia (calcium 2.76 mmol/l), normal renal profile and serum electrophoresis, vitamin D deficiency [25(OH)D of 12 nmol/l] and an elevated parathyroid hormone (PTH) of 172 pg/ml. There was no evidence of malignancy on femoral biopsies. Densitometry (DXA) revealed T-scores of - 4.0 (0.607 g/cm2) at lumbar spine and - 4.9 (0.401 g/cm2) at distal forearm. Neck imaging did not identify a parathyroid adenoma, and her hyperparathyroidism was managed non-surgically. She was treated with zoledronic acid for osteoporosis, with subsequent lifelong denosumab planned. This case highlights the impact of undiagnosed PHPT on bone loss and the rare possibility of atraumatic hip fractures. It also emphasizes the value of DXA screening and investigation for secondary causes of osteoporosis in older adults.
- 28 May 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Open AccessPrimary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case report
Primary hyperparathyroidism (PHPT) affects up to 1.5% of older adults, causes bone loss at cortical sites and increases fracture risk. However, atraumatic hip fractures due to PHPT are rare. We report the case of an older female diagnosed with PHPT after presenting with atraumatic bilateral neck of femur fractures. An 82-year-old white woman was referred to the emergency department with progressive left hip pain over two months and was unable to bear weight on presentation. There was no history of trauma, falls, prior fracture or diagnosis of osteoporosis. X-ray of hips showed a displaced left neck of femur fracture and a non-displaced healing right neck of femur fracture. Pelvic computed tomography (CT) confirmed X-ray findings and showed callus formation suggesting subacute fractures with no evidence of destructive lesions. Blood tests revealed hypercalcemia (calcium 2.76 mmol/l), normal renal profile and serum electrophoresis, vitamin D deficiency [25(OH)D of 12 nmol/l] and an elevated parathyroid hormone (PTH) of 172 pg/ml. There was no evidence of malignancy on femoral biopsies. Densitometry (DXA) revealed T-scores of - 4.0 (0.607 g/cm2) at lumbar spine and - 4.9 (0.401 g/cm2) at distal forearm. Neck imaging did not identify a parathyroid adenoma, and her hyperparathyroidism was managed non-surgically. She was treated with zoledronic acid for osteoporosis, with subsequent lifelong denosumab planned. This case highlights the impact of undiagnosed PHPT on bone loss and the rare possibility of atraumatic hip fractures. It also emphasizes the value of DXA screening and investigation for secondary causes of osteoporosis in older adults.
- 23 February 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (4) , 1007-1008
The risk of hypocalcaemia after denosumab administration
- 23 February 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (4) , 1007-1008
The risk of hypocalcaemia after denosumab administration
- 5 March 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (4) , 765-766
Early administration of zoledronic acid after hip fracture
- 5 March 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (4) , 765-766
Early administration of zoledronic acid after hip fracture
- 11 December 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (5) , e1713-e1714
Letter to Editor From McCarroll et al: “Approach to the Patient: Normocalcemic Primary Hyperparathyroidism”
- 11 December 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (5) , e1713-e1714
Letter to Editor From McCarroll et al: “Approach to the Patient: Normocalcemic Primary Hyperparathyroidism”
- 9 August 2024
- Published by Springer Nature in Osteoporosis International
- Vol. 35 (10) , 1869-1870
Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis
- 9 August 2024
- Published by Springer Nature in Osteoporosis International
- Vol. 35 (10) , 1869-1870
Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis
- Open Access
- 13 April 2024
- Published by Springer Nature in Osteoporosis International
- Vol. 35 (7) , 1299-1302
Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review
Introduction Transient hypercalcaemia due to teriparatide occurs in up to 11% of patients though delayed hypercalcaemia (> 24 h post injection) is rare. We report the case of a female who developed significant delayed hypercalcaemia after teriparatide treatment for osteoporosis and review other cases in the literature to date. Case report A 72-year-old female on teriparatide for the treatment of osteoporosis was found to have hypercalcaemia (3.30 mmol/l) on routine testing approximately 3 months after starting therapy. Serum calcium pretreatment was normal at 2.39 mmol/l. She was admitted to the hospital for investigations which identified a serum 25-hydroxyvitamin D of 94 nmol/l, a low parathyroid hormone of 6.0 pg/ml, and normal test results for 1,25 dihydroxyvitamin D (115 pmol/l), parathyroid hormone-related peptide (< 1.4 pmol/ml), serum electrophoresis and angiotensin-converting enzyme (39 IU/l). CT abdomen, pelvis, and thorax revealed no evidence of malignancy and an isotope bone scan ruled out skeletal metastases. Serum calcium normalised (2.34 mmol/l) several days after stopping teriparatide and calcium supplements and administering intravenous fluid. On restarting teriparatide, delayed hypercalcaemia reoccurred and treatment was switched to denosumab. Discussion Delayed moderate to severe hypercalcaemia (serum calcium > 3.0 mmol/l) due to teriparatide is rare but may lead to therapy withdrawal. The underlying predisposing risk factors remain unclear and highlight the importance of a routine serum calcium assessment on therapy.
- 13 April 2024
- Published by Springer Nature in Osteoporosis International
- Vol. 35 (7) , 1299-1302
Open AccessDelayed and significant hypercalcaemia due to teriparatide therapy: a case report and review
Introduction Transient hypercalcaemia due to teriparatide occurs in up to 11% of patients though delayed hypercalcaemia (> 24 h post injection) is rare. We report the case of a female who developed significant delayed hypercalcaemia after teriparatide treatment for osteoporosis and review other cases in the literature to date. Case report A 72-year-old female on teriparatide for the treatment of osteoporosis was found to have hypercalcaemia (3.30 mmol/l) on routine testing approximately 3 months after starting therapy. Serum calcium pretreatment was normal at 2.39 mmol/l. She was admitted to the hospital for investigations which identified a serum 25-hydroxyvitamin D of 94 nmol/l, a low parathyroid hormone of 6.0 pg/ml, and normal test results for 1,25 dihydroxyvitamin D (115 pmol/l), parathyroid hormone-related peptide (< 1.4 pmol/ml), serum electrophoresis and angiotensin-converting enzyme (39 IU/l). CT abdomen, pelvis, and thorax revealed no evidence of malignancy and an isotope bone scan ruled out skeletal metastases. Serum calcium normalised (2.34 mmol/l) several days after stopping teriparatide and calcium supplements and administering intravenous fluid. On restarting teriparatide, delayed hypercalcaemia reoccurred and treatment was switched to denosumab. Discussion Delayed moderate to severe hypercalcaemia (serum calcium > 3.0 mmol/l) due to teriparatide is rare but may lead to therapy withdrawal. The underlying predisposing risk factors remain unclear and highlight the importance of a routine serum calcium assessment on therapy.
- Open Access
- 2 August 2023
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (11) , 1917-1926
The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture—results of a large observational cohort study
Summary Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture; however, the mechanism is unclear. PPI users taking calcium supplements were more likely to have hyperparathyroidism compared to non-users (OR 1.56, CI 1.08–2.23, p = 0.018). This highlights the importance of monitoring PPI use, especially in older adults. Purpose Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture. Hyperparathyroidism may be implicated, but few studies have considered this relationship. This study evaluated the relationship between PPI use and hyperparathyroidism in older adults. Methods Participants were from the TUDA study, a large cross-sectional cohort of older Irish adults. Participants with an estimated glomerular filtration rate (eGFR) < 30 ml/min and serum calcium > 2.5 mmol/l were excluded to avoid hyperparathyroidism due to chronic renal disease and primary hyperparathyroidism. Hyperparathyroidism was defined as a parathyroid hormone (PTH) > 65 pg/ml. Multivariate regression models were used to analyse the relationship between PPI use and hyperparathyroidism. Results A total of 4139 participants met the inclusion criteria, of whom 37.8% (n = 1563) were taking PPI medication. PPI use was identified in 41.4% of calcium supplement users and 35.4% of non-calcium supplement users. Overall, compared to non-users of PPIs, those taking PPIs were older (74.8 vs 72.9 years, p < 0.001) and had a higher prevalence of hyperparathyroidism (17.8 vs 11.0%, p < 0.001). In those taking calcium supplements (but not in non-users), PPI use was significantly associated with hyperparathyroidism (OR 1.56, CI 1.08–2.23, p = 0.018) after adjusting for age, sex, body mass index, serum vitamin D, eGFR, timed-up-and-go, dairy intake, medications, and comorbidities. Discussion The results are consistent with the hypothesis of PPIs reducing calcium absorption, leading to a rise in PTH which could mediate increased fracture risk. No relationship of PPI use with hyperparathyroidism was observed in non-users of calcium supplements, possibly owing to lower dietary calcium intake. These results highlight the importance of monitoring PPI use, especially in older adults at risk of fracture.
- 2 August 2023
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (11) , 1917-1926
Open AccessThe association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture—results of a large observational cohort study
Summary Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture; however, the mechanism is unclear. PPI users taking calcium supplements were more likely to have hyperparathyroidism compared to non-users (OR 1.56, CI 1.08–2.23, p = 0.018). This highlights the importance of monitoring PPI use, especially in older adults. Purpose Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture. Hyperparathyroidism may be implicated, but few studies have considered this relationship. This study evaluated the relationship between PPI use and hyperparathyroidism in older adults. Methods Participants were from the TUDA study, a large cross-sectional cohort of older Irish adults. Participants with an estimated glomerular filtration rate (eGFR) < 30 ml/min and serum calcium > 2.5 mmol/l were excluded to avoid hyperparathyroidism due to chronic renal disease and primary hyperparathyroidism. Hyperparathyroidism was defined as a parathyroid hormone (PTH) > 65 pg/ml. Multivariate regression models were used to analyse the relationship between PPI use and hyperparathyroidism. Results A total of 4139 participants met the inclusion criteria, of whom 37.8% (n = 1563) were taking PPI medication. PPI use was identified in 41.4% of calcium supplement users and 35.4% of non-calcium supplement users. Overall, compared to non-users of PPIs, those taking PPIs were older (74.8 vs 72.9 years, p < 0.001) and had a higher prevalence of hyperparathyroidism (17.8 vs 11.0%, p < 0.001). In those taking calcium supplements (but not in non-users), PPI use was significantly associated with hyperparathyroidism (OR 1.56, CI 1.08–2.23, p = 0.018) after adjusting for age, sex, body mass index, serum vitamin D, eGFR, timed-up-and-go, dairy intake, medications, and comorbidities. Discussion The results are consistent with the hypothesis of PPIs reducing calcium absorption, leading to a rise in PTH which could mediate increased fracture risk. No relationship of PPI use with hyperparathyroidism was observed in non-users of calcium supplements, possibly owing to lower dietary calcium intake. These results highlight the importance of monitoring PPI use, especially in older adults at risk of fracture.
- Open Access
- 22 May 2023
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (1) , 271-276
Knowledge gap in a cross section of Irish general practitioners prescribing denosumab for osteoporosis
Background Denosumab is commonly used by general practitioners (GPs) in Ireland to treat osteoporosis though drug holidays are not recommended with rebound bone loss and risk of vertebral fractures if stopped. We aimed to investigate GP practice and knowledge regarding denosumab including use and reasons for use, therapy duration, blood monitoring and recommended vitamin D status/calcium intake on treatment, staff administering, methods of recall, delays in receiving injections, management of and awarenes of guidelines if stopped, reasons for stopping and concerns about same. Methods GPs were contacted (n = 846) by email and invited to complete an online anonymous survey comprising 25 questions in January 2022. We collated responses and explored for differences between GP principals/trainers and GP trainees. Results There were 146 responses. Sixty-seven percent were female and 50% were GP principal/trainers. Forty-three percent used denosumab as a first line therapy citing convenience in 32% of cases. Half (50%) envisaged therapy for 3–5 years and 15% lifelong use. A fifth (21%) had no concerns about it being stopped (11% trainors vs 31% trainees, P = 0.002). If stopped, 41% cited opting for a drug holiday with monitoring. Forty percent of GPs gave patients a reminder card for the next injection and 27% had an alert system. Conclusion We identified a knowledge gap in denosumab prescribing among a sample of Irish GPs. Findings suggest a need for education to increase awareness around denosumab use and to consider recall systems in GP practices as suggested elsewhere to ensure persistence with therapy.
- 22 May 2023
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (1) , 271-276
Open AccessKnowledge gap in a cross section of Irish general practitioners prescribing denosumab for osteoporosis
Background Denosumab is commonly used by general practitioners (GPs) in Ireland to treat osteoporosis though drug holidays are not recommended with rebound bone loss and risk of vertebral fractures if stopped. We aimed to investigate GP practice and knowledge regarding denosumab including use and reasons for use, therapy duration, blood monitoring and recommended vitamin D status/calcium intake on treatment, staff administering, methods of recall, delays in receiving injections, management of and awarenes of guidelines if stopped, reasons for stopping and concerns about same. Methods GPs were contacted (n = 846) by email and invited to complete an online anonymous survey comprising 25 questions in January 2022. We collated responses and explored for differences between GP principals/trainers and GP trainees. Results There were 146 responses. Sixty-seven percent were female and 50% were GP principal/trainers. Forty-three percent used denosumab as a first line therapy citing convenience in 32% of cases. Half (50%) envisaged therapy for 3–5 years and 15% lifelong use. A fifth (21%) had no concerns about it being stopped (11% trainors vs 31% trainees, P = 0.002). If stopped, 41% cited opting for a drug holiday with monitoring. Forty percent of GPs gave patients a reminder card for the next injection and 27% had an alert system. Conclusion We identified a knowledge gap in denosumab prescribing among a sample of Irish GPs. Findings suggest a need for education to increase awareness around denosumab use and to consider recall systems in GP practices as suggested elsewhere to ensure persistence with therapy.